PhaseBio Pharmaceuticals Growth, Revenue, Number of Employees and Funding
Estimated Revenue & Financials
- PhaseBio Pharmaceuticals's estimated revenue is currently $5.3M per year.
- PhaseBio Pharmaceuticals's estimated revenue per employee is $146389
- PhaseBio Pharmaceuticals has 36 Employees.
- PhaseBio Pharmaceuticals grew their employee count by 44% last year.
- PhaseBio Pharmaceuticals currently has 1 job openings.
|Susan Arnold||VP Preclinical & CMC|
|Jim Ballance||VP Research/Scientific Affairs|
|John Sharp||Chief Financial Officer|
|Susan Maloney-Kopf||Senior Director|
|John Lee||Chief Medical Officer|
|Michael York||VP Corporate Development & Commercial Strategy|
|Glen Burkhardt||Vice President of Human Resources|
What Is PhaseBio Pharmaceuticals?
PhaseBio is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary indications. Our lead product candidate is PB2452, a novel reversal agent for the antiplatelet drug ticagrelor, and our second product candidate is PB1046, a once-weekly fusion protein for the treatment of pulmonary arterial hypertension. PB1046 utilizes our elastin-like polypeptide technology, which also serves as the engine for our preclinical pipeline. Our proprietary technology platform uses recombinant elastin-like polypeptide (ELP) biopolymers to control the half-life, bioavailability and physical characteristics of molecules for ease of administration. The compounds are engineered for a specific rate of absorption to enhance efficacy and reduce side effects, which may lead to less-frequent dosing and better patient compliance. PB1046 is a vasoactive intestinal peptide (VIP) receptor agonist that leverages our ELP technology for once-weekly dosing. PB1046 is being evaluated in clinical studies in pulmonary arterial hypertension (PAH) and in preclinical studies for the treatment of cardiomyopathy associated with dystrophinopathies. PhaseBio recently concluded a Phase 2a trial of PB1046 in patients with heart failure with reduced ejection fraction. We are also evaluating our development candidate PB2452, a reversal agent for the antiplatelet therapy ticagrelor, in clinical trials. PB2452 was exclusively licensed from MedImmune, the global biologics research and development arm of AstraZeneca, for global development and commercialization by PhaseBio. PhaseBio continues to explore opportunities to apply our ELP biopolymer technology to compounds that may benefit from its unique properties. We are privately owned, with headquarters and research laboratories in Malvern, PA.keywords:N/A
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
PhaseBio Pharmaceuticals News
13, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on ...
Alps Advisors Inc. bought a new position in shares of PhaseBio Pharmaceuticals Inc (NASDAQ:PHAS) in the 2nd quarter, according to the ...
MALVERN, Pa. and SAN DIEGO, Aug. 26, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (PHAS), a clinical-stage ...